🔎 Trials Near Me

Dachaigh › Ro-throm › Louisiana

Sgrùdaidhean clionaigeach Ro-throm ann an Louisiana

Tha 24 sgrùdaidhean airson Ro-throm a’ lorg phàirtichean aig làraichean ann an Louisiana.

Bailtean ann an Louisiana

Teacsa sgrùdaidh oifigeil (Beurla)

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Velocity Clinical Research - Baton Rouge, Baton Rouge
  • Tandem Clinical Research - Marrero, Marrero
A’ fastadhÌre 3
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • Ima Clinical Research- Monroe, Monroe
A’ fastadhÌre 3
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07684144

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Cardiovascular Associates Research, LLC, Covington
  • Tandem Clinical Research - Marrero, Marrero
A’ fastadhÌre 3
Aoisean 45 gu 99 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07037433

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • Pennington Biomed Res Ctr, Baton Rouge
A’ fastadhÌre 3
Aoisean 8 gu 18 · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT07253285

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • BRCR Global Louisiana, Gretna
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07837973

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • Pennington Biomedical Research Center, Baton Rouge
  • IMA Clinical Research Monroe-Main, Monroe
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07794579

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • Southern Clin Research, Zachary
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT07668414

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Care Access - New Iberia, New Iberia
  • Louisiana Research Center, Shreveport
A’ fastadhÌre 3
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Velocity Clinical Research, Lafayette
A’ fastadhÌre 3
Aoisean 6 gu 17 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Care Access - New Iberia, New Iberia
  • Louisiana Research Center, Shreveport
A’ fastadhÌre 3
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06937086

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • IMA Clinical Research Monroe - Armand, Monroe
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Clinical Trials Management, LLC d/b/a Flourish Research, Metairie
  • IMA Clinical Research Monroe - Armand, Monroe
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Care Access - Shreveport 2, Shreveport
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07369011

Impact of Lean Pork on Endothelial Function in Perimenopause

  • Pennington Biomedical Research Center, Baton Rouge
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 40 gu 55 · Banairean · Air ùrachadh 22 Sult 2026 · NCT06976112

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Care Access - Lake Charles (Bayou Pines), Lake Charles
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07321886

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Monroe
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07784270

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Baton Rouge
  • AURORA-2 Clinical Site, Metairie
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Baton Rouge
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT07743463

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Elevate Clinical Research, Lake Charles
  • Nola Care Clinical Research Center, Metairie
  • DelRicht Clinical Research, LLC, New Orleans
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07351058

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Ascension DePaul Health, New Orleans
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT07351045

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Shreveport
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT07284901

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Pennington Biomedical Research Center, Baton Rouge
A’ fastadhÌre 3
Aoisean 18 gu 99 · Gach gnè · Air ùrachadh 27 Lùna 2026 · NCT07575399

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Baton Rouge
A’ fastadhÌre 3
Aoisean 18 gu 79 · Gach gnè · Air ùrachadh 10 Lùna 2026 · NCT07654361

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

  • Pennington Biomedical Research Center, Baton Rouge
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 18 gu 42 · Gach gnè · Air ùrachadh 8 Gibl 2026 · NCT04583514

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.